Drug Trial Radar · NCT07024563
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 14, 2025
Primary completion
Nov 29, 2028
Study completion Apr 19, 2030
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
Conditions
- IgAN
- IgAVN
- Immunoglobulin A Nephropathy
- Immunoglobulin A Vasculitis Associated Nephritis
- Henoch-schonlein Purpura Nephritis
- IgA Vasculitis
Interventions
RavulizumabDrug
Participants will receive Ravulizumab via intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Proteinuria Based on Urine Protein to Creatinine Ratio (UPCR) at Week 34Time frame: Baseline, Week 34
Locations
19 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Palo Alto, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
London, Ontario, Canada · Not yet recruiting
Research Site
Toronto, Ontario, Canada · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Berlin, Germany · Not yet recruiting
Research Site
Essen, Germany · Not yet recruiting
Research Site
Genova, Italy · Recruiting
Research Site
Roma, Italy · Recruiting
Research Site
Torino, Italy · Recruiting
Research Site
Wakayama, Japan · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Almería, Spain · Not yet recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Seville, Spain · Recruiting
Research Site
Taipei, Taiwan · Recruiting
Research Site
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.